JP2005508148A - ｓｅｓ−３の同定、およびその使用 - Google Patents

ｓｅｓ−３の同定、およびその使用 Download PDF

Info

Publication number: JP2005508148A
Authority: JP; Japan
Prior art keywords: ses; nucleic acid; elegans; acid molecule; isolated nucleic
Prior art date: 2001-06-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2003507120A

Other languages

English (en)

Japanese (ja)

Other versions

JP2005508148A5 (fr

Inventor

ラールフ・バウマイスター

ベルナルト・ラコウスキ

シュテファン・アイマー

Original Assignee

アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-06-22

Filing date

2002-06-24

Publication date

2005-03-31

2002-06-24 Application filed by アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング filed Critical アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング

2005-03-31 Publication of JP2005508148A publication Critical patent/JP2005508148A/ja

2005-10-27 Publication of JP2005508148A5 publication Critical patent/JP2005508148A5/ja

Status Pending legal-status Critical Current

Links

108090000623 proteins and genes Proteins 0.000 claims abstract description 90
150000007523 nucleic acids Chemical class 0.000 claims abstract description 59
108020004707 nucleic acids Proteins 0.000 claims abstract description 52
102000039446 nucleic acids Human genes 0.000 claims abstract description 52
102000004169 proteins and genes Human genes 0.000 claims abstract description 49
239000000126 substance Substances 0.000 claims abstract description 37
230000009261 transgenic effect Effects 0.000 claims abstract description 25
208000024827 Alzheimer disease Diseases 0.000 claims abstract description 18
239000013598 vector Substances 0.000 claims abstract description 10
238000004519 manufacturing process Methods 0.000 claims abstract description 9
239000003814 drug Substances 0.000 claims abstract description 8
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
101100465890 Caenorhabditis elegans sel-12 gene Proteins 0.000 claims description 56
230000000694 effects Effects 0.000 claims description 28
101100339496 Caenorhabditis elegans hop-1 gene Proteins 0.000 claims description 24
125000003275 alpha amino acid group Chemical group 0.000 claims description 15
238000000034 method Methods 0.000 claims description 13
101000617536 Homo sapiens Presenilin-1 Proteins 0.000 claims description 12
108700028369 Alleles Proteins 0.000 claims description 11
239000012634 fragment Substances 0.000 claims description 10
150000001413 amino acids Chemical class 0.000 claims description 9
101000617546 Homo sapiens Presenilin-2 Proteins 0.000 claims description 7
108020004414 DNA Proteins 0.000 claims description 6
239000002299 complementary DNA Substances 0.000 claims description 6
238000011835 investigation Methods 0.000 claims description 6
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
101001050886 Homo sapiens Lysine-specific histone demethylase 1A Proteins 0.000 claims description 5
230000004770 neurodegeneration Effects 0.000 claims description 5
208000015122 neurodegenerative disease Diseases 0.000 claims description 5
208000012902 Nervous system disease Diseases 0.000 claims description 4
208000025966 Neurological disease Diseases 0.000 claims description 4
230000007423 decrease Effects 0.000 claims description 4
102100024985 Lysine-specific histone demethylase 1A Human genes 0.000 claims description 3
241000700605 Viruses Species 0.000 claims description 3
230000000295 complement effect Effects 0.000 claims description 3
150000001875 compounds Chemical class 0.000 claims description 3
102000055060 human PSEN1 Human genes 0.000 claims description 3
239000002773 nucleotide Substances 0.000 claims description 3
125000003729 nucleotide group Chemical group 0.000 claims description 3
241000255601 Drosophila melanogaster Species 0.000 claims description 2
238000012986 modification Methods 0.000 claims description 2
230000004048 modification Effects 0.000 claims description 2
239000013612 plasmid Substances 0.000 claims description 2
241001515965 unidentified phage Species 0.000 claims description 2
241000001357 Cystobacterineae bacterium Species 0.000 claims 2
102000053602 DNA Human genes 0.000 claims 2
102000012419 Presenilin-2 Human genes 0.000 claims 2
230000002159 abnormal effect Effects 0.000 claims 1
108010050254 Presenilins Proteins 0.000 abstract description 30
102000015499 Presenilins Human genes 0.000 abstract description 22
230000035772 mutation Effects 0.000 description 37
241001465754 Metazoa Species 0.000 description 16
230000017448 oviposition Effects 0.000 description 13
108020004999 messenger RNA Proteins 0.000 description 9
102100022033 Presenilin-1 Human genes 0.000 description 8
108091028043 Nucleic acid sequence Proteins 0.000 description 7
230000005856 abnormality Effects 0.000 description 7
230000007547 defect Effects 0.000 description 7
238000002703 mutagenesis Methods 0.000 description 7
231100000350 mutagenesis Toxicity 0.000 description 7
108090000765 processed proteins & peptides Proteins 0.000 description 7
101710137189 Amyloid-beta A4 protein Proteins 0.000 description 6
101710151993 Amyloid-beta precursor protein Proteins 0.000 description 6
102100022704 Amyloid-beta precursor protein Human genes 0.000 description 6
238000000636 Northern blotting Methods 0.000 description 6
108700019146 Transgenes Proteins 0.000 description 6
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 6
229920001184 polypeptide Polymers 0.000 description 6
102000004196 processed proteins & peptides Human genes 0.000 description 6
102100022036 Presenilin-2 Human genes 0.000 description 5
210000004027 cell Anatomy 0.000 description 5
241000282412 Homo Species 0.000 description 4
230000006399 behavior Effects 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
238000011161 development Methods 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
238000009396 hybridization Methods 0.000 description 4
230000001629 suppression Effects 0.000 description 4
101100478118 Caenorhabditis elegans spe-4 gene Proteins 0.000 description 3
241000255581 Drosophila <fruit fly, genus> Species 0.000 description 3
108700024394 Exon Proteins 0.000 description 3
102100038195 Exonuclease mut-7 homolog Human genes 0.000 description 3
101000958030 Homo sapiens Exonuclease mut-7 homolog Proteins 0.000 description 3
108010070047 Notch Receptors Proteins 0.000 description 3
102000005650 Notch Receptors Human genes 0.000 description 3
102000035195 Peptidases Human genes 0.000 description 3
108091005804 Peptidases Proteins 0.000 description 3
101000612288 Pinus strobus Putative oxygen-evolving enhancer protein 1 Proteins 0.000 description 3
239000004365 Protease Substances 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
238000012217 deletion Methods 0.000 description 3
230000037430 deletion Effects 0.000 description 3
235000013601 eggs Nutrition 0.000 description 3
230000001747 exhibiting effect Effects 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
238000012545 processing Methods 0.000 description 3
102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
101710096214 Alanine aminotransferase 1 Proteins 0.000 description 2
241000244203 Caenorhabditis elegans Species 0.000 description 2
101100074828 Caenorhabditis elegans lin-12 gene Proteins 0.000 description 2
206010061818 Disease progression Diseases 0.000 description 2
241000244206 Nematoda Species 0.000 description 2
230000005913 Notch signaling pathway Effects 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
230000004913 activation Effects 0.000 description 2
108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000002950 deficient Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
230000005750 disease progression Effects 0.000 description 2
208000015756 familial Alzheimer disease Diseases 0.000 description 2
108020001507 fusion proteins Proteins 0.000 description 2
102000037865 fusion proteins Human genes 0.000 description 2
238000013537 high throughput screening Methods 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
239000003550 marker Substances 0.000 description 2
230000017854 proteolysis Effects 0.000 description 2
239000000523 sample Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
208000037259 Amyloid Plaque Diseases 0.000 description 1
102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 1
108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 1
108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 description 1
101100455522 Caenorhabditis elegans spr-5 gene Proteins 0.000 description 1
101100048436 Caenorhabditis elegans unc-1 gene Proteins 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
241000195493 Cryptophyta Species 0.000 description 1
208000031124 Dementia Alzheimer type Diseases 0.000 description 1
108010035533 Drosophila Proteins Proteins 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
241000233866 Fungi Species 0.000 description 1
101100192145 Homo sapiens PSEN1 gene Proteins 0.000 description 1
241000179764 Isatis elegans Species 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
208000024556 Mendelian disease Diseases 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
108010036933 Presenilin-1 Proteins 0.000 description 1
108010036908 Presenilin-2 Proteins 0.000 description 1
240000004604 Ptychosperma elegans Species 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
241000269370 Xenopus <genus> Species 0.000 description 1
238000007792 addition Methods 0.000 description 1
239000008272 agar Substances 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000001715 anti-suppressor Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
238000010367 cloning Methods 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
102000055037 human PSEN2 Human genes 0.000 description 1
230000036512 infertility Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
230000001418 larval effect Effects 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
239000003446 ligand Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
230000004660 morphological change Effects 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000008569 process Effects 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000011664 signaling Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
238000000638 solvent extraction Methods 0.000 description 1
230000021595 spermatogenesis Effects 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
229940038773 trisodium citrate Drugs 0.000 description 1
108700026220 vif Genes Proteins 0.000 description 1

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
- C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
- C07K14/43545—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes from Caenorhabditis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Tropical Medicine & Parasitology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Neurology (AREA)
Molecular Biology (AREA)
Neurosurgery (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Toxicology (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychiatry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Hospice & Palliative Care (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

JP2003507120A 2001-06-22 2002-06-24 ｓｅｓ−３の同定、およびその使用 Pending JP2005508148A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE10130247A DE10130247A1 (de)	2001-06-22	2001-06-22	Identifizierung von ses-3 sowie dessen Verwendungen
PCT/EP2002/006964 WO2003000717A2 (fr)	2001-06-22	2002-06-24	Identification de ses-3 et leurs utilisations

Publications (2)

Publication Number	Publication Date
JP2005508148A true JP2005508148A (ja)	2005-03-31
JP2005508148A5 JP2005508148A5 (fr)	2005-10-27

Family

ID=7689142

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2003507120A Pending JP2005508148A (ja)	2001-06-22	2002-06-24	ｓｅｓ−３の同定、およびその使用

Country Status (7)

Country	Link
US (2)	US20050059586A1 (fr)
EP (1)	EP1404710B1 (fr)
JP (1)	JP2005508148A (fr)
AT (1)	ATE512981T1 (fr)
AU (1)	AU2002350406A1 (fr)
DE (1)	DE10130247A1 (fr)
WO (1)	WO2003000717A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7693122B2 (en)	2003-08-21	2010-04-06	Ntt Docomo, Inc.	Resource reservation in a wireless network with distributed medium access control

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3658172A4 (fr)	2017-07-25	2021-05-05	TrueBinding, Inc.	Traitement du cancer par blocage de l'interaction de tim-3 et de son ligand
CN113711036B (zh)	2019-01-30	2025-03-18	真和制药有限公司	抗gal3抗体及其用途
CN116157151A (zh)	2020-05-26	2023-05-23	真和制药有限公司	通过阻断半乳凝素-3治疗炎性疾病的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU728251B2 (en) *	1995-09-27	2001-01-04	Trustees Of Columbia University In The City Of New York, The	Identification of SEL-12 and uses thereof
US6909029B2 (en) *	2000-10-02	2005-06-21	Smithkline Beecham Corporation	Caenorhabditis elegans chemosensory bioassay for seven transmembrane receptor ligands

2001
- 2001-06-22 DE DE10130247A patent/DE10130247A1/de not_active Ceased
2002
- 2002-06-24 AU AU2002350406A patent/AU2002350406A1/en not_active Abandoned
- 2002-06-24 US US10/481,581 patent/US20050059586A1/en not_active Abandoned
- 2002-06-24 WO PCT/EP2002/006964 patent/WO2003000717A2/fr not_active Ceased
- 2002-06-24 EP EP02751064A patent/EP1404710B1/fr not_active Expired - Lifetime
- 2002-06-24 JP JP2003507120A patent/JP2005508148A/ja active Pending
- 2002-06-24 AT AT02751064T patent/ATE512981T1/de active
2007
- 2007-07-24 US US11/782,116 patent/US20070293450A1/en not_active Abandoned

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7693122B2 (en)	2003-08-21	2010-04-06	Ntt Docomo, Inc.	Resource reservation in a wireless network with distributed medium access control

Also Published As

Publication number	Publication date
EP1404710B1 (fr)	2011-06-15
DE10130247A1 (de)	2003-01-16
WO2003000717A2 (fr)	2003-01-03
US20070293450A1 (en)	2007-12-20
AU2002350406A1 (en)	2003-01-08
WO2003000717A3 (fr)	2003-10-30
ATE512981T1 (de)	2011-07-15
EP1404710A2 (fr)	2004-04-07
US20050059586A1 (en)	2005-03-17

Legal Events

Date	Code	Title	Description
2005-06-21	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050620
2008-05-07	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080507
2008-08-08	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080807
2008-08-15	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080814
2008-11-08	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081107
2008-12-09	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081209
2009-03-10	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090309
2009-04-02	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090310
2009-07-14	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090714
2009-10-20	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091019
2009-11-25	A911	Transfer to examiner for re-examination before appeal (zenchi)	Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20091124
2009-12-21	A912	Re-examination (zenchi) completed and case transferred to appeal board	Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20091218
2012-08-29	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120828

Publication	Publication Date	Title
Guo et al.	1999	Drosophila presenilin is required for neuronal differentiation and affects notch subcellular localization and signaling
JP2000506375A (ja)	2000-05-30	アルツハイマー病に関連する核酸およびタンパク質、ならびにその使用
AU2002248224B2 (en)	2006-11-09	Methods and compositions for the identification and treatment of neurodegenerative disorders
EP1147123B1 (fr)	2006-12-20	Nouveaux recepteurs olfactifs chez les drosophiles
AU2002248224A1 (en)	2003-02-06	Methods and compositions for the identification and treatment of neurodegenerative disorders
EP1324652B1 (fr)	2007-04-18	Drosophila melanogaster transgenique exprimant la proteine beta-amyloide
US20070293450A1 (en)	2007-12-20	Identification of ses-3 and the uses of same
JP3932358B2 (ja)	2007-06-20	ブラディオン遺伝子導入ショウジョウバエ株
US6943278B2 (en)	2005-09-13	Transgenic Drosophila having a disrupted Parkin gene and exhibits reduced climbing ability
US6468770B1 (en)	2002-10-22	Nucleic acids and proteins of D. melanogaster insulin-like genes and uses thereof
US20080168573A1 (en)	2008-07-10	Identification of ses-1 and the uses of the same
JPH11512611A (ja)	1999-11-02	ｓｅｌ−１２の同定およびその使用
AU2001272238A1 (en)	2002-01-02	CLK-2, CEX-7 and COQ-4 genes, and uses thereof
US7125687B1 (en)	2006-10-24	Presenilin enhancers assays
WO1999054436A2 (fr)	1999-10-28	Acides nucleiques et proteines de genes de type insuline derives de c. elegans, et leurs utilisations
AU2001262988A1 (en)	2002-02-07	Presenilin enhancers
Lazakovitch et al.	2005	nfi-1 affects behavior and life-span in C. elegans but is not essential for DNA replication or survival
US20050164194A1 (en)	2005-07-28	Growth regulating proteins
WO2008061674A2 (fr)	2008-05-29	Utilisation d'un modèle animal et procédé permettant de tester des médicaments et des traitements contre le cancer chez des humains
Duncan	2002	The Drosophila dynamitin gene: using molecular dynamite to study the developmental roles of cytoplasmic dynein

JP2005508148A - ｓｅｓ−３の同定、およびその使用 - Google Patents

Info

Links

Images

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (2)

Family

ID=7689142

Family Applications (1)

Country Status (7)

Cited By (1)

Families Citing this family (3)

Family Cites Families (2)

Cited By (1)

Also Published As

Similar Documents

Legal Events